[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367470-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367470-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","development-of-umuc-1-targeted-nemo-particles-with-ph-activatable-mri-signals-for-enhanced-detection-of-malignant-breast-cancer-cells","Development of uMUC-1 Targeted NEMO Particles with pH-Activatable MRI Signals for Enhanced Detection of Malignant Breast Cancer Cells","","Magnetic resonance imaging (MRI) detects more breast cancers than mammography due to its superior soft-tissue contrast, yet it misdiagnoses about 40% of benign tumors as malignant because clinically used contrast agents are nonspecific. To address this, receptor-targeted, pH-sensitive Nano-Encapsulated Manganese Oxide (NEMO) particles were developed as an alternative T1-weighted MRI contrast agent. A uMUC-1 targeting peptide (EPPT) promoted preferential endocytosis by malignant cells and activated T1 MRI signals in acidic endosomes/lysosomes within clinically relevant timeframes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/development-of-umuc-1-targeted-nemo-particles-with-ph-activatable-mri-signals-for-enhanced-detection-of-malignant-breast-cancer-cells/367470/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/development-of-umuc-1-targeted-nemo-particles-with-ph-activatable-mri-signals-for-enhanced-detection-of-malignant-breast-cancer-cells/367470.png","ImageObject",300,407,{"name":42,"@type":43},"Jordan Avery","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why do current MRI contrast agents still cause false-positive breast cancer diagnoses?","Question",{"text":63,"@type":64},"Clinically used contrast agents such as gadolinium chelates are nonspecific and become “ON” signals wherever the agent accumulates, including benign and malignant, highly vascularized tissues.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does EPPT play in the developed imaging particles?",{"text":68,"@type":64},"EPPT is a breast cancer targeting peptide against underglycosylated mucin-1, promoting preferential endocytosis of NEMO particles by malignant cells.",{"name":70,"@type":61,"acceptedAnswer":71},"How do pH-activatable NEMO particles generate T1 MRI contrast?",{"text":72,"@type":64},"NEMO remains largely inactive at physiological pH, but robustly dissociates into Mn2+ in the acidic endosomes/lysosomes, coordinating with water to produce bright T1 MRI signal.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367470,1790210453,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","This article is licensed under CC-BY 4.0   \n[www.acsabm.org](www.acsabm.org)  Article   \nDevelopment of uMUC‑1 Targeted NEMO Particles with pHActivatable MRI Signals for Enhanced Detection of Malignant Breast Cancer Cells  \nDhruvi M. Panchal, Alexia R. Gorman, Celia Martinez de la Torre, Barrick M. Silverman, Anthony J. Scalzo, Hunter T. Snoderly, Benoit Driesschaert, and Margaret F. Bennewitz*  \n Cite This: ACS Appl. Bio Mater. 2025, 8, 4251−4261  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Magnetic resonance imaging (MRI) detects more breast cancers than mammography due to its superior soft tissue contrast; however, it still misdiagnoses 40% of benign tumors as malignant due to clinically used nonspecific contrast agents (e.g., gadolinium chelates). To overcome this limitation, we developed receptor-targeted, pH-sensitive Nano-Encapsulated Manganese Oxide (NEMO) particles as an alternative T1-weighted MRI contrast agent. A breast cancer targeting peptide, EPPT, against underglycosylated mucin-1, promotes preferential endocytosis of NEMO particles by malignant cells and specific activation of the MRI signal inside low pH endosomes/lysosomes. In just 30 min, EPPT-NEMO particles produced rapid and robust T1- eighted MRI contrast inside T47D breast cancer cells that reached 276% signal enhancement, whi was significantly brighter than  \nMCF10A benign control cells ( 57% enhancement). Mn cellular  \ncontent further confirmed peptide targeting specificity, while confocal microscopy showed the colocalization of EPPT-NEMO particles with endosomes and lysosomes. EPPT-NEMO particles show promise as alternative T1-weighted MRI contrast agents, producing significantly brighter signals in breast cancer cells compared to benign cells within clinically relevant timeframes. These advancements in targeted MRI contrast agents could lead to improved accuracy in breast cancer diagnosis and ultimately to better patient outcomes.  \nKEYWORDS: magnetic resonance imaging, manganese oxide, nanoparticles, uMUC-1, breast cancer  \n■ INTRODUCTION  \nBreast cancer is the second most common cancer worldwide and is the fourth greatest cause of cancer-related death in the world.1 The diagnostic stage and molecular subtype greatly impact the patient's prognosis. The 5-year survival rate decreases from 99% for localized disease to 30% with distant metastasis.2 The earlier the tumor is diagnosed, the sooner treatment can be applied to increase survival. Currently, mammography is the primary screening tool that aims to promote early detection; however, it misses 20% of breast cancers, often in young women with dense breasts.3,4 Moreover, 50% of healthy women will experience a false positive diagnosis over 10 years of annual screening, wherein a benign mass is incorrectly diagnosed as malignant.3 False positives cause anxiety, distress, and increased medical expenses due to additional testing.5  \nAs an adjunct to mammography, magnetic resonance imaging (MRI) is used for high-risk women who have a strong family history of breast cancer or dense breast tissue. Compared to mammography, MRI has superior contrast to  \nvisualize structural differences within soft tissue and detect more breast cancers.2,3 MRI also produces 3D images of the tumor and does not require X-ray radiation or breast compression. Despite increased sensitivity, RI still misses  \n5−15% of breast cancers6 and misdiagnoses 40% of benign masses as breast cancers7 due to the intravenous contrast agent currently used (e.g., gadolinium chelates). Clinically used gadolinium (Gd) chelates are always “ON”, creating a signal wherever the agent accumulates in the body. Moreover, Gd chelates lack specificity8 and enter highly vascularized tissues of benign and malignant tumors.  \nIn light of these challenges, there is an unmet need for alternative MRI contrast agents that offer enh","cbCaifKFs2PEXxqT","https://ap.wps.com/l/cbCaifKFs2PEXxqT","pdf",3372935,11,"English","# Abstract\n# Introduction\n## Breast cancer burden and screening limitations\n## MRI advantages and remaining diagnostic specificity issues\n## pH-switchable manganese oxide as an alternative contrast approach","[{\"question\":\"Why do current MRI contrast agents still cause false-positive breast cancer diagnoses?\",\"answer\":\"Clinically used contrast agents such as gadolinium chelates are nonspecific and become “ON” signals wherever the agent accumulates, including benign and malignant, highly vascularized tissues.\"},{\"question\":\"What role does EPPT play in the developed imaging particles?\",\"answer\":\"EPPT is a breast cancer targeting peptide against underglycosylated mucin-1, promoting preferential endocytosis of NEMO particles by malignant cells.\"},{\"question\":\"How do pH-activatable NEMO particles generate T1 MRI contrast?\",\"answer\":\"NEMO remains largely inactive at physiological pH, but robustly dissociates into Mn2+ in the acidic endosomes/lysosomes, coordinating with water to produce bright T1 MRI signal.\"}]","Development of uMUC-1 Targeted NEMO Particles with pH-Activatable MRI Signals for Enhanced Detection of Malignant Breast Cancer Cells | PDF",1790170944,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/240f63d3af164dc89ea87f5358bd918e.webp",983,1296,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e461382d193761cbed557498d2cd908.webp",982,1295,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb74bba6ef841455c293bd44d0e93eb1.webp",981,1293,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0949f6d9332075d8eaa07a4ca319ac0.webp",980,1292]